Tuesday 17 November 2026 Sign in / SubscribeFree daily emailMarket analysisEnterpriseVigiEye regulatory newsCompePharma CRM & HR →
The business of pharma
Approvals & launches

Lakefront Biotherapeutics sets up second €50m stock repurchase, again through Morgan Stanley

The Euronext- and NASDAQ-listed company will buy back up to 4,604,550 of its own shares by 31 March 2027, a month after finishing its first €50m programme.

16 Nov 2026 · Lakefront Biotherapeutics · Company news

Lakefront Biotherapeutics NV (Euronext and NASDAQ: LKFT) said on 16 November 2026 that it will repurchase up to €50m of its own stock, capped at 4,604,550 shares. The window stays open until 31 March 2027 at the latest, so purchases could continue for about four and a half months.

Subscribe to keep reading

$4.99 / month

  • Every article, analysis and opinion piece on CompePharma and VigiEye
  • One subscription for both sites, cancel any time

Already a subscriber? Enter your email below: we'll send you a sign-in link. No password needed.

We'll email you a link to confirm your address, then take you to secure checkout (Stripe). Billed monthly until you cancel; access starts at once, so the 14-day withdrawal right ends when it does. Already a subscriber? Enter your email and the link will sign you in. See our terms and privacy policy.

Written by CompePharma's editorial system from the company's filing; claims are the company's. AI-assisted; check the source before acting. Not investment advice.

More Approvals & launchesAll →